Condition
Malignant Pleural Mesothelioma
Estimated Enrollment: 24
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment
Study ID Numbers: 2015-0856|NCI-2016-01923
Study First Received: November 7, 2016
Last Updated: April 19, 2017
Estimated Primary Completion Date: June 2020
Primary Outcome Measures:
Treatment-Related Toxicity of Adding Pembrolizumab with Radiation Therapy in Participants who Have Undergone at Least 2 Cycles of Chemotherapy and Possible Lung-Sparing Surgery|Treatment-Related Toxicity of Adding Pembrolizumab with Radiation Therapy in Participants who Have Possibly Received Prior Chemotherapy and No Surgery|Tumor Response
Sponsors and Collaborators:
M.D. Anderson Cancer Center|Merck Sharp & Dohme Corp.
Website Link: https://ClinicalTrials.gov/show/NCT02959463
